ZNTL
Price:
$4.92
Market Cap:
$350.24M
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Industry
Biotechnology
IPO Date
2020-04-03
Stock Exchange
NASDAQ
Ticker
ZNTL
According to Zentalis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.84. This represents a change of 210.14% compared to the average of -0.92 of the last 4 quarters.
The mean historical PE Ratio of Zentalis Pharmaceuticals, Inc. over the last ten years is -11.05. The current -2.84 PE Ratio has changed 2.47% with respect to the historical average. Over the past ten years (40 quarters), ZNTL's PE Ratio was at its highest in in the March 2024 quarter at 28.80. The PE Ratio was at its lowest in in the September 2021 quarter at -177.42.
Average
-11.05
Median
-11.24
Minimum
-22.60
Maximum
-0.71
Discovering the peaks and valleys of Zentalis Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 24.86%
Maximum Annual PE Ratio = -0.71
Minimum Annual Increase = -80.11%
Minimum Annual PE Ratio = -22.60
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -0.71 | -45.65% |
| 2024 | -1.30 | -61.63% |
| 2023 | -3.39 | -24.61% |
| 2022 | -4.50 | -80.11% |
| 2021 | -22.60 | 24.86% |
| 2020 | -18.10 | 0.63% |
| 2019 | -17.98 | -9.30% |
The current PE Ratio of Zentalis Pharmaceuticals, Inc. (ZNTL) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.80
5-year avg
-6.50
10-year avg
-11.05
Zentalis Pharmaceuticals, Inc.’s PE Ratio is less than Pliant Therapeutics, Inc. (-0.58), greater than Artiva Biotherapeutics, Inc. (-3.27), less than Instil Bio, Inc. (-1.01), greater than Immix Biopharma, Inc. (-10.33), greater than Shattuck Labs, Inc. (-11.88), less than Sutro Biopharma, Inc. (-1.54), less than ALX Oncology Holdings Inc. (-1.17), greater than MacroGenics, Inc. (-3.55), less than Whitehawk Therapeutics Inc (-2.44), less than Precision BioSciences, Inc. (-2.04),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.58 | $65.64M | |
| -3.27 | $286.72M | |
| -1.01 | $48.69M | |
| -10.33 | $516.82M | |
| -11.88 | $358.52M | |
| -1.54 | $244.98M | |
| -1.17 | $259.65M | |
| -3.55 | $248.21M | |
| -2.44 | $203.00M | |
| -2.04 | $95.95M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Zentalis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Zentalis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Zentalis Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Zentalis Pharmaceuticals, Inc. (ZNTL)?
What is the highest PE Ratio for Zentalis Pharmaceuticals, Inc. (ZNTL)?
What is the 3-year average PE Ratio for Zentalis Pharmaceuticals, Inc. (ZNTL)?
What is the 5-year average PE Ratio for Zentalis Pharmaceuticals, Inc. (ZNTL)?
How does the current PE Ratio for Zentalis Pharmaceuticals, Inc. (ZNTL) compare to its historical average?